Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

ram.

IND Filed with FDA to Enable Clinical Testing of New Oral Drug for Bone Disease

In August 2007, the Company filed an Investigational New Drug Exemption (IND) with the FDA's Division of Endocrinologic and Metabolic Drugs for a newly formulated compound, known as G4544. Developed out of a joint collaboration with Emisphere Technologies, Inc., G4544 is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite. This compound is a highly potent inhibitor of calcium release from bone. Diseases associated with accelerated bone loss include hypercalcemia, bone metastases, Paget's disease and osteoporosis. Genta currently intends to manage the clinical development process of oncology indications and to seek a development and commercial partner for non-malignant metabolic bone diseases. Assuming regulatory concurrence with the IND plan to establish bioequivalence with the FDA-approved parenteral product, Genta expects to initiate the initial clinical trial of G4544 in the second half of 2007.

Stock Trading and Capital Structure

In July, Genta was notified by NASDAQ that the Company has demonstrated compliance with all NASDAQ Marketplace rules. As a consequence, the NASDAQ Listings Qualifications Panel determined that Genta's common stock will continue to be listed on the NASDAQ Global Market. As part of the plan to establish compliance, Genta stockholders approved a one-for-six reverse split of the Company's shares of common stock, which reduced the number of outstanding shares to approximately 31 million. The Company's common stock temporarily trades under the symbol "GNTAD". On or about August 10, 2007, the Company expects that the common stock will resume trading under its former symbol, "GNTA".

Financial Information

All share and per share data included in this press release have been retroactively adjusted to account for the effect of the 1-for-6 reverse stock split on July 13, 2007. The Co
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... $15 million milestone payment from GSK related to advancing the ... familial amyloid polyneuropathy (FAP).  "We are very ... , and plan to report data from the Phase 2/3 ... fifteen months of dosing and are now receiving ISIS-TTR Rx ...
(Date:3/2/2015)... BETHESDA, Md. , March 2, 2015 /PRNewswire/ ... treating and preventing autoimmune diseases, announced today that it ... 714) from Amgen (NASDAQ: AMGN ). Under ... the rights to develop, manufacture and commercialize AMG 714 ... . Concurrently, Amgen has been granted an exclusive option ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... Part D beneficiaries who enter the "donut hole," where ... prescription costs, are twice as likely to discontinue  their ... or generic medications, a new study published today in ... The study conducted by researchers from Harvard ...
... Aug. 16, 2011 BD (Becton, Dickinson and Company) ... technology company, today announced the completion of its acquisition ... the PhaSeal® System, the leading closed-system drug transfer device ... packaged in vials.  The acquisition expands the scope of ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3BD Completes Acquisition of Carmel Pharma 2BD Completes Acquisition of Carmel Pharma 3
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... 02, 2015 Four Seasons Resort Maui at ... 25th anniversary this year, having officially opened its doors on ... resort is honoring over 70 employees who started on Day ... amongst the approximately 400 original employees. The celebration will ... Lawn. , This Four Seasons flagship resort, the ...
(Date:3/2/2015)... Houston, TX (PRWEB) March 02, 2015 ... CV? How should physicians request references? When are interviews ... physicians analyze employment opportunities?, Both training and practicing physicians ... answers to these questions and more at the PracticeLink ... March 18. The drop-in Job Fair is from 5:30 ...
(Date:3/2/2015)... Éminence Organic Skin Care, the leader ... to announce the launch of the Balance Collection, an ... solution for those with combination skin. The Balancing Masque ... jar to separate the products, consists of the Charcoal ... Moisturizer Duo, also in a divided jar, contains both ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 Security ... the ancillary benefits market, announced the addition of ... PrimeStar Individual Vision Insurance launched today, complete with ... plan will utilize the VSP® Vision Care network ... the private practice space. The PrimeStar Select Vision ...
Breaking Medicine News(10 mins):Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 3Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2
... ENT and ... “Holes in My Shoes.” The film made its broadcast premier last Holiday Season on ... at 10pm. , ... (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is proud to ...
... ... in Certain Populations , ... Valencia, CA (PRWEB) June 25, 2010 -- The United States (U.S.) Centers for ... Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB). In these landmark guidelines, CDC ...
... Ross ... to Membership organizations that will help increase member retention, reduce cost and grow revenues. ... Atlanta, GA (PRWEB) ... MRM software and services to the American Automobile Association, announced today a strategic partnership ...
... Days ... the reports from northeastern Brazil where up to 100,000 people are feared to have lost ... Lakewood Ranch, ... towns “wiped off” the map. These are the reports from northeastern Brazil where up to ...
... York, June 25, 2010 Cardiac allograft vasculopathy (CAV), ... transplantation, occurs when blood vessels in a transplanted heart ... muscle or sudden death. Ascertaining benefit from appropriate treatment ... of the lack of a standard nomenclature. In an ...
... ... method that allows for significant risk reduction for index investing. Investors can ... limited or capped while reinvesting index gains accrued to lock in both ... of the principal value is invested and backed by FDIC insured bank ...
Cached Medicine News:Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 3Health News:Ross Group Inc Expands Offerings to Membership Clients 2Health News:Ross Group Inc Expands Offerings to Membership Clients 3Health News:ShelterBox Response Team Leaving for Flood Struck Brazil 2Health News:ShelterBox Response Team Leaving for Flood Struck Brazil 3Health News:New ISHLT cardiac allograft vasculopathy standardized nomenclature 2Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 2Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 3
Bougie Urethrotomes for slitting the female urethra and for meatus stenosis in males...
... Elite System™ and USA ... utilized for incision of ... neck contractures under direct ... converts the visual urethrotome ...
... Elite System™ and USA ... utilized for incision of ... neck contractures under direct ... converts the visual urethrotome ...
ACMI urethrotomes are available in two distinct styles to meet your specific professional needs. The Classic Series™ Otis Urethrotome consists of a blade, straight tip, and ball tip, with an av...
Medicine Products: